While medical device shortages are nothing new, the FDA said it is becoming more concerned that supply chain disruptions are ...

Venova Medical recently announced the enrollment of the first patients in the company’s VENOS-2 early feasibility study o ...

The FDA is urging Congress to implement mandatory medical device shortage reporting to address growing vulnerabilities in the ...

Before 1998, urokinase was considered standard therapy for the management of occluded hemodialysis catheters. The dose of 5000 units per port appears on the FDA-approved labeling for urokinase.

Central venous catheter-related blood stream infection (CRBSI) is a major cause of morbidity and mortality in patients with end-stage renal disease treated with chronic hemodialysis. Risk factors ...

The FDA warned the nation about the growing vulnerability of the medical device supply chain and its effects on public health, particularly among pediatric patients, in a Jan. 16 news release.

Shares of CorMedix CRMD rose nearly 30% on Tuesday after management announced fourth-quarter and full-year 2024 preliminary sales figures. CorMedix’s Preliminary Sales Figures Beat Estimates CorMedix ...

The effectiveness of alteplase and urokinase in restoring adequate hemodialysis blood-flow rates was examined. A retrospective review of the medical records of hemodialysis patients with central ...